BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Mobius Theraputics™ Granted Orphan Drug Designation for Cornea Indication


1/21/2011 9:34:27 AM

ST. LOUIS, MO--(Marketwire - January 21, 2011) - Mobius Therapeutics™, LLC, a St. Louis-based ophthalmic company, has received Orphan Drug Designation from the Food and Drug Administration for their platform product, Mitosol™, for use in "Prevention of recurrence of pterygium after its surgical excision."

By granting orphan drug status to Mitosol™ for this indication, Mobius Therapeutics™ will expand its reach to general ophthalmologists and ocular surface specialists, as these surgeons routinely perform pterygium removal procedures.

"The designation of Mitosol™ as an orphan drug will help Mobius Therapeutics™ provide surgeons and allied health personnel with improved convenience, safety and precision in their treatment of pterygium," said Ed Timm, President of Mobius Therapeutics™.

Orphan Drug Designation is granted specifically to treat rare medical diseases or conditions. "Removal of pterygium is a specialized indication for the use of Mitosol™ in ophthalmology, precisely the type of application to be protected by orphan drug status," said Timm.

Pterygium is a triangular patch of tissue that obstructs vision by growing over the inner side of the eye and is usually caused by degeneration of the cornea due to prolonged exposure to sun or wind. The use of Mitosol™ following the removal of pterygium helps stop the recurrence of similar obstructions.

"The final approval of Mitosol™ will greatly improve the treatment of pterygium," said Timm. "It will help provide patients with quality assurance, surgeons with precision and convenience, and our investors with unprecedented value."

About Mobius Therapeutics, LLC:
Mobius Therapeutics is an early stage venture focused on ophthalmic surgery solutions. Its first product, Mitosol, is a system for delivering antifibrotic agents in glaucoma, refractive, and corneal surgery. It is awaiting regulatory approval, with additional product applications in earlier stages of development.


CONTACT:
Jim Anderson
Mobius Therapeutics, LLC
+1 314-615-6930
Email Contact

Andy Likes
The Vandiver Group, Inc.
+1 314-991-4641
Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES